Compare BigBearai Holdings Inc (BBAI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Moderna, Inc. — how do they compare? BigBearai Holdings Inc trades at $3.17 (market cap $1.48B), while Moderna, Inc. trades at $67.08 (market cap $26.76B). The key difference: Moderna, Inc. is far larger — about 18.1× BigBearai Holdings Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBAI | MRNA | |
|---|---|---|
Market Cap | $1.48B | $26.76B |
Sector | Technology | Health |
52-Week High | $8.91 | $81.80 |
52-Week Low | $3.05 | $22.36 |
Enterprise Value | $1.16B | $22.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.08, down 5.81% in the past 24 hours, with a bearish technical signal from moving averages. The company reported revenue of $127.67M in 2025 but a net loss of $293.91M, reflecting a negative net margin of -226.69%. Recent news highlights AI growth opportunities in defense and airport security, yet profitability challenges persist.
Outlook remains cautious due to ongoing losses and negative cash flow from operations. Investment opportunities include backlog growth and debt reduction, but risks include high SG&A expenses and reliance on government contracts. Analyst consensus is mixed with 75% hold ratings, indicating uncertainty about near-term performance.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
